Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review.

Authors :: Orita A
Hoshina D
Hirosaki K
Source :: Clinical and experimental dermatology [Clin Exp Dermatol] 2022 Jul; Vol. 47 (7), pp. 1372-1374. Date of Electronic Publication: 2022 Apr 22.
Publication Year :: 2022
Abstract: We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.<br /> (© 2022 British Association of Dermatologists.)

Subjects :: Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized
Humans
Interleukin-23
Pyoderma Gangrenosum drug therapy

Full Text Access

Tools